Catalyst Biosciences, Inc. (CBIO) EPS Estimated At $-0.59

July 11, 2018 - By Margaret Guttierez

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Logo

Analysts expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report $-0.59 EPS on August, 2.They anticipate $1.94 EPS change or 76.68 % from last quarter’s $-2.53 EPS. After having $-0.56 EPS previously, Catalyst Biosciences, Inc.’s analysts see 5.36 % EPS growth. The stock decreased 0.08% or $0.01 during the last trading session, reaching $11.78. About 171,976 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has risen 487.47% since July 12, 2017 and is uptrending. It has outperformed by 474.90% the S&P500.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $140.60 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

More notable recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: which released: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Biosciences, Inc …” on June 18, 2018, also with their article: “2 Biotech Stocks That Tanked This Week: Can They Recover?” published on June 22, 2018, published: “Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today” on June 18, 2018. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) were released by: and their article: “Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research” published on July 10, 2018 as well as‘s news article titled: “Catalyst Biosciences Joins the Russell 2000® Index” with publication date: June 25, 2018.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.